Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
- S. Barrington, N. Mikhaeel, B. Cheson
- MedicineJournal of clinical oncology : official journal…
- 20 September 2014
This article comprises the consensus reached to update guidance on the use of PET-CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practice and late-phase trials.
18F-FDG PET Uptake Characterization Through Texture Analysis: Investigating the Complementary Nature of Heterogeneity and Functional Tumor Volume in a Multi–Cancer Site Patient Cohort
Heterogeneity quantification and volume may provide valuable complementary information for volumes above 10 cm3, although the complementary information increases substantially with larger volumes.
Intrinsic Brain Activity in Altered States of Consciousness
- M. Boly, C. Phillips, Steven Laureys
- Psychology, BiologyAnnals of the New York Academy of Sciences
- 1 May 2008
Results suggest that slow coherent spontaneous BOLD fluctuations cannot be exclusively a reflection of conscious mental activity, but may reflect default brain connectivity shaping brain areas of most likely interactions in a way that transcends levels of consciousness, and whose functional significance remains largely in the dark.
18F-FDG PET in children with lymphomas
18F-FDG-PET is a useful tool for evaluating children with lymphomas, at various stages of their disease, and large prospective studies are needed to appreciate its real impact on patient management.
Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.
- N. Paquet, A. Albert, J. Foidart, R. Hustinx
- MedicineJournal of nuclear medicine : official…
- 1 May 2004
The SUVs measured in normal liver and mediastinum in cancer-free patients are stable over time, no matter which normalization is used, and correcting for blood glucose level increases the variability of the values and should therefore be avoided.
Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).
- A. Cottereau, S. Becker, M. Meignan
- MedicineAnnals of oncology : official journal of the…
- 1 April 2016
TMTV0 appears as an independent predictor of PTCL outcome and combined with PIT, it could identify different risk categories at diagnosis and warrants further validation as a prognostic marker.
Functional neuroanatomy underlying the clinical subcategorization of minimally conscious state patients
The proposed subcategorization of MCS based on the presence or absence of command following showed a different functional neuroanatomy and patients in MCS+ showed preserved metabolism and functional connectivity in language networks arguably reflecting some additional higher order or extended consciousness albeit devoid of clinical verbal or nonverbal expression.
Central modulation in cluster headache patients treated with occipital nerve stimulation: an FDG-PET study
Metabolic normalization in the pain neuromatrix and lack of short-term changes induced by the stimulation might support the hypothesis that ONS acts in drCCH through slow neuromodulatory processes.
Imaging gliomas with positron emission tomography and single-photon emission computed tomography.
The overall clinical utility of single photon emission computed tomography (SPECT) and PET in characterizing recurrent lesions remains dependent on the availability of effective treatments and is thus mostly suited to the evaluation of treatment response in experimental protocols designed to improve the patients' outcome.
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.
The data suggest the potential of whole-body positron emission tomography (PET) to detect preclinical relapse in patients with Hodgkin's disease and help identify patients requiring salvage chemotherapy at the time of minimal disease rather than at thetime of clinically overt relapse.